Emcure Pharmaceuticals initial public offerings (IPO), which opened for subscription on Wednesday, was fully subscribed by the later half of the first day of bidding, driven by strong demand from non-institutional investors.
The issue has been subscribed 1.22 times in the retail category and 1.92 times in the NII portion, on June 3. However, there have been no bids yet in the QIB category.
(This is a developing story)